| 臺大學術典藏 |
2009 |
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis
|
Forrest G.N.; Dromer F.; Lortholary O.; Alexander B.D.; HSIN-YUN SUN; Houston S.; House A.A.; Orloff S.; Garcia-Diaz J.; Kalil A.C.; Munoz P.; Lyon G.M.; Somani J.; Gupta K.L.; Del Busto R.; Pruett T.L.; Sifri C.D.; Limaye A.P.; John G.T.; Klintmalm G.B.; Pursell K.; Stosor V.; Morris M.I.; Dowdy L.A.; Wray D.; Huprikar S.; Johnson L.B.; Humar A.; Razonable R.R.; Husain S.; Singh N. |
| 臺大學術典藏 |
2018-09-10T14:51:58Z |
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-infected adults treated with rilpivirine or efavirenz for 96 weeks in the ECHO and THRIVE trials
|
Tebas, P. and Sension, M. and Arribas, J. and Duiculescu, D. and Florence, E. and Hung, C.-C. and Wilkin, T. and Vanveggel, S. and Stevens, M. and Deckx, H.; CHIEN-CHING HUNG |
| 臺大學術典藏 |
2020-09-30T03:22:38Z |
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-infected adults treated with rilpivirine or efavirenz for 96 weeks in the ECHO and THRIVE trials
|
Tebas P.; Sension M.; Arribas J.; Duiculescu D.; Florence E.; CHIEN-CHING HUNG; Wilkin T.; Vanveggel S.; Stevens M.; Deckx H. |
| 臺大學術典藏 |
2022-09-09T05:50:01Z |
Lipid lowering in primary prevention: The lower is better, but where to settle?
|
WEI-SHIUNG YANG |
| 國立成功大學 |
2018-09 |
Lipid Lowering Therapy for Acute Coronary Syndrome and Coronary Artery Disease: Highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients
|
Li;Yi-Heng;Chao;Ting-Hsing;Liu;-Yen, Ping;Ueng;Kwo-Chang;Yeh;Hung-I |
| 臺大學術典藏 |
2020-02-25T09:24:04Z |
Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? – Data from a multicenter registry cohort study in Taiwan
|
Yeh, Y.-T.; Yin, W.-H.; Tseng, W.-K.; FANG-JU LIN; Yeh, H.-I.; Chen, J.-W.; Wu, Y.-W.; Wu, C.-C. |
| 臺大學術典藏 |
2020-03-04T09:03:05Z |
Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? – Data from a multicenter registry cohort study in Taiwan
|
Yeh Y.-T.; Yin W.-H.; Tseng W.-K.; Lin F.-J.; Yeh H.-I.; Chen J.-W.; Wu Y.-W.; CHAU-CHUNG WU; Taiwanese Secondary Prevention for Patients with AtheRosCLErotic Disease (T-SPARCLE) Registry Investigators |
| 臺大學術典藏 |
2020-09-30T08:49:26Z |
Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? – Data from a multicenter registry cohort study in Taiwan
|
Yeh Y.-T.; Yin W.-H.; Tseng W.-K.; Lin F.-J.; Yeh H.-I.; Chen J.-W.; YEN-WEN WU; Wu C.-C.; Taiwanese Secondary Prevention for Patients with AtheRosCLErotic Disease (T-SPARCLE) Registry Investigators |
| 臺大學術典藏 |
2021-03-18T08:54:16Z |
Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? – Data from a multicenter registry cohort study in Taiwan
|
Yeh Y.-T.; Yin W.-H.; Tseng W.-K.; Lin F.-J.; Yeh H.-I.; Chen J.-W.; YEN-WEN WU; Wu C.-C.; Taiwanese Secondary Prevention for Patients with AtheRosCLErotic Disease (T-SPARCLE) Registry Investigators |
| 臺大學術典藏 |
2018-09-10T18:02:50Z |
Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? �V Data from a multicenter registry cohort study in Taiwan
|
Yeh, Y.-T. and Yin, W.-H. and Tseng, W.-K. and Lin, F.-J. and Yeh, H.-I. and Chen, J.-W. and Wu, Y.-W. and Wu, C.-C.; FANG-JU LIN; YEN-WEN WU |
| 嘉南藥理大學 |
2021 |
Lipid Metabolism and its Mechanism Triggered by Supercritical CO2 Extract of Adlay (Coix lacryma-jobi var. ma-yuen (Rom. Caill.) Stapf) Bran in High-Fat Diet Induced Hyperlipidemic Hamsters
|
Huang, Chiao-Chih; Lin, Tzu-Ching; Liu, Chiung-Hui; Hu, Hao-Chun; Yu, Szu-Yin; Wu, Shu-Jing; Yen, Ming-Hong; Tsai, Yi-Hong; Chang, Fang-Rong |
| 國立成功大學 |
2016-06 |
Lipid metabolism during WSSV infection in shrimp
|
Cheng, Cheng-Shun; Wang, Han-Ching |
| 臺北醫學大學 |
2003 |
Lipid metabolism in hypercholesterolemic rats affected by feeding cholesterol-free diets containing different amounts of undialyzed soybean protein fraction.
|
陳俊榮; Chen; JR; Chiou; SF; Suetsuna; K; Yang; HY; and Yang; SC |
| 臺北醫學大學 |
1997 |
Lipid metabolism is altered by nebacitin in rats fed cooked-stored polished rice as the only dietary carbohydrate with or without exogenou cholesterol.
|
鄭心嫻; Cheng HH and Yu WW |
| 國立成功大學 |
2023 |
Lipid metabolomic signature might predict subclinical atherosclerosis in patients with active rheumatoid arthritis
|
Chang, Chang C.-K.;Chang, K.-H.;Cheng, W.-C.;Chen, P.-K.;Chiang, E.-P.I.;Chang, S.-H.;Li, Y.-C.;Chen, Chen C.-H.;Chen, D.-Y. |
| 國立中山大學 |
1977 |
Lipid Monolayer Phase Transitions: Theoretical Consideration
|
H.L. Scott;W.H. Cheng |
| 臺大學術典藏 |
2018-09-10T03:41:38Z |
Lipid myopathy associated with renal tubular acidosis and spastic diplegia in two brothers
|
Tung, Y.-C.;Tsau, Y.-K.;Chu, L.-W.;Young, C.;Shen, Y.-Z.; YONG-KWEI TSAU |
| 臺大學術典藏 |
2021-01-08T06:17:28Z |
Lipid myopathy associated with renal tubular acidosis and spastic diplegia in two brothers
|
Yi-Ching Tung;Tsau Y.-K.;Chu L.-W.;Young C.;Shen Y.-Z.; YI-CHING TUNG; Tsau Y.-K.; Chu L.-W.; Young C.; Shen Y.-Z. |
| 國立臺灣大學 |
2001 |
Lipid Myopathy Associated with Renal Tubular Scidosis and Spastic Diplegia in Two Brothers
|
童怡靖; 曹永魁; 朱麗雯; 楊千立; 沈友仁; TUNG, YI-CHING; TSAU, YONG-KWEI; CHU, LI-WEN; YOUNG, CHAINLLIE; SHEN, YU-ZEN |
| 國家衛生研究院 |
2024-03-14 |
Lipid nanoparticle-encapsulated DNA vaccine robustly induce superior immune responses to the mRNA vaccine in Syrian hamsters
|
Liao, HC;Shen, KY;Yang, CH;Chiu, FF;Chiang, CY;Chai, KM;Huang, WC;Ho, HM;Chen, YH;Huang, MS;Liao, CL;Chen, HW;Huang, MH;Liu, SJ |
| 臺北醫學大學 |
2008 |
Lipid nanoparticles as vehicles for topical psoralen
|
方嘉郎; Fang JY; Fang CL; Liu CH; Su YH |
| 東海大學 |
2008 |
Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC)
|
Fang, J.-Y.a , Fang, C.-L.b, Liu, C.-H.c, Su, Y.-H.a |
| 臺大學術典藏 |
2020-03-02T07:14:45Z |
Lipid nanoparticles for hepatic delivery of small interfering RNA
|
Wang X.; Terp M.C.; Wu Y.; Teng L.; Mao Y.; Wang F.; Xue W.; Jacob S.T.; Ghoshal K.; Lee R.J.; Lee L.J.; Yu B.; SHU-HAO HSU; Zhou C. |
| 臺大學術典藏 |
2018-09-10T09:17:05Z |
Lipid nanoparticles for hepatic delivery of small interfering RNA
|
Yu, B. and Hsu, S.-H. and Zhou, C. and Wang, X. and Terp, M.C. and Wu, Y. and Teng, L. and Mao, Y. and Wang, F. and Xue, W. and Jacob, S.T. and Ghoshal, K. and Lee, R.J. and Lee, L.J.; SHU-HAO HSU |
| 嘉南藥理大學 |
2009-09 |
Lipid nanoparticles with different oil/fatty ester ratios as carriers of buprenorphine and its prodrugs for injection
|
Jhi-Joung Wang; Kuo-Sheng Liu; K.C. Sung; Chia-Yin Tsai; Jia-You Fang |
